Health Care Providers' Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar.

Autor:	Gasteiger, Chiara, Lobo, Maria, Wong, Lun Shen, Murdoch, Rachel, Dalbeth, Nicola
Předmět:	HEALTH services accessibility GENERIC drug substitution NURSES' attitudes ATTITUDES of medical personnel WORK CROSS-sectional method RHEUMATOLOGY BIOSIMILARS MEDICAL care costs PHARMACISTS' attitudes SATISFACTION RHEUMATOLOGISTS T-test (Statistics) EXPERIENTIAL learning NURSES GOVERNMENT agencies EMPLOYEES' workload DESCRIPTIVE statistics ADALIMUMAB DATA analysis software
Zdroj:	ACR Open Rheumatology; Dec2023, Vol. 5 Issue 12, p644-651, 8p
Abstrakt:	Objective: Transitioning patients to biosimilars has become common to reduce costs and improve access. However, it is unclear how the transition process impacts health care providers at the frontline of the brand change. This study explores health care providers' experiences of a mandatory brand change to an adalimumab biosimilar. Methods: A cross‐sectional study was conducted in Aotearoa New Zealand with 164 providers involved in the nationwide adalimumab brand change. Rheumatologists (n = 39), rheumatology nurses (n = 16), and pharmacists (n = 109) completed a survey that assessed their satisfaction with logistics and supply, information and education, support, and administrative workload and reported what did and did not go well during the transition. Results: The mean satisfaction score (0‐10) with the transition was 5.7 (SD = 2.6). Providers were the least satisfied with training for the biosimilar device, information from government agencies, and administrative workload during the transition. Satisfaction with adalimumab safety, efficacy and device quality, and the availability of sharps bins, alcohol wipes, and patient support was lower following the transition. Satisfaction with administrative workload (B = 0.37, P < 0.001) and training for the device (B = 0.20, P = 0.020) predicted overall satisfaction. Providers reported that a poorly implemented initial authorization process, loss of a patient support program, and insufficient communication between providers complicated the transition. The citrate‐free preservative and longer authorization duration after the transition were viewed positively. Conclusion: Providers experienced an increased workload and reported less satisfaction with the biosimilar following the transition. Experiences may be improved by ensuring training for the device, a high‐quality patient support program, and functioning authorization processes throughout the transition. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text